PsyKey Inc.: You may remember the bullrun from Q1-2021 when CEOS topped $0.48 before retreating to current levels. The team pumping CEOS earlier this year was right about its potential, unfortunately just 7 - 8 months too early.
Bad for early investors, great for you.
All of the potential that drove CEOS to nearly $0.50 is now coming to fruition. Recent tweets indicate that the company has all of its supply chain, contractual and legal, and production capabilities in place to begin stocking shelves with its mushroom infused coffees and teas, oral supplements, and single serve drink mixes.
Even more impressive is the team that they have assembled over the last few months while readying supply chain, technology, distribution, formulation, and up-listing and cross-listing options.
If you like low float (109M), heavy insider ownership (65%), first mover, first to market, biotechnology, patents, psychedelics, reverse mergers, and multiple catalysts in the coming weeks, check out PsyKey Inc.
A little birdy has said that a PR is imminent, although that is unconfirmed.
All information is best available. Do your own research.
PsyKey Inc. is vertically integrated in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations, for use in its premium quality functional product lines to help improve and optimize everyday life.
Psykey Inc. is also engaged in the scientific development of patentable technologies pertaining to the composition, bioavailability, and targeted delivery of entheogenic based therapeutics for the fast-evolving psychedelics market.
PsyKey Inc. is currently in the development stages of patentable cutting-edge novel technologies, that will directly support and impact the fast-evolving therapeutic psilocybin market. These technologies are focused on composition, bioavailability, and targeted delivery.
Status on December 01, 2021
Recent Twitter updates from the official Twitter (@psykeyworld) stated:
"Production is close to beginning. Sourcing is complete... Final third party testing of our ingredients and formulation is taking place. We are very close!!"
PsyKey Live will provide counselling on demand at any time and location with registered psychologists in every area of mental wellness, allowing individuals to take control of their mental health. Offering simple, direct access to caring mental health professionals for all conditions, from daily challenges to more severe treatments, the App will allow users to book an appointment on their phone or desktop to receive immediately counseling. The Company expects the App to be live on the Apple Store and Google in the coming months. Revenue will be generated on a commission basis per appointment booked, and also from in App advertising of health related products and featured clinics.
Psykey’s retail products include Functional Mushroom coffees and teas, oral supplements, and single serve drink mixes. All products are developed with premium quality ingredients and are designed to provide the best possible results for consumers. Our formulations are created utilizing functional mushrooms that have been used in traditional Chinese medicine and holistic healing for hundreds of years. These mushrooms include: Reishi, Chaga, Lions Mane, Turkey Tail, Cordyceps, and Shiitake mushrooms. Coffee and tea products are manufactured by Cordoba Coffee with over 35 years of experience in the brewed beverage industry. Oral supplements and single serve drink mixes are manufactured by North American based GMP & site licensed manufacturing facilities.
Benefits of Medical Mushrooms
MycoVita is a Biotech company focused on the development of functional foods and products, that support optimal health and wellbeing through science-backed formulations and research. MycoVita holds numerous formulations that are composed of natural occurring compounds sourced only from the highest quality raw ingredients, under the supervision and guidance of its world-class team.
The MycoVita team includes Dr. Omon Isikhuemhen who is an internationally recognized researcher and professor in the field of mushroom science and fungal biotechnology. Dr. Isikhuemhen's credentials include a Bachelor of Science with honors, a Master's of Science in Botany, as well as a Doctor of Philosophy in Microbiology. Dr. Isikhuemhen is a trailblazer in research and development that has resulted in numerous scientific publications and technological advancements.
This strategic partnership will provide PsyKey Inc. exclusive access to formulations, science-backed research, supply chain security, and new potential distribution channels.
"Partnering with MycoVita will not only provide PsyKey the opportunity to offer consumers unmatched quality and efficacy in its product offerings, but it will also open doors in the mushroom industry and mycology world by working alongside Dr. Isikhuemhen. This will allow us to further gain and develop opportunity to provide long-term growth and new revenue streams for the company," said Amar Bhatal, president of CeCors Inc.
Zealous Inc. is a Canadian Biotechnology company whose focus is the development of psilocybin and psilocin, commercially produced using its proprietary bioreactor fermentation technology. Zealous Inc's impressive bioengineering team includes ten PhDs who have a successful track record of producing 99+% pure cytosine, orotate, and beta-nicotinamide mononucleotide on a commercial scale.
Zealous Inc. also has a successful history in product development and commercialization utilizing active compound identification, formula development, recipe design and optimization, as well as consumer trials and clinical studies. The Zealous team has over 15 years of experience in the food, beverage, and supplement industries. Senior management has successfully managed over 40 stock keeping units (SKU) and has launched 13 new products/formulas in both the United States and Canada.
Professional Gardener partnership will focus on the development and distribution of unique, innovative products for the fast-growing, commercial mushroom production industry, organic farming and home-based markets. The products will be focused on the ability to increase yields, optimize potency, while maintaining organic standing and certification.
In his 27-year tenure with one of the largest banks in North America, Royal Bank of Canada (RBC), as well as North America's leading diversified financial services companies. Mr. Gibbins served as Managing Director and Global Head of Foreign Exchange & Commodity Derivatives for RBC Capital Markets' Global Treasury Services and RBC Capital Markets' Executive Committee. Mr. Gibbins was appointed to the European Central Bank's advisory board at its formation in 1999 and was also invited to join the Bank of England's advisory board in 2000. After his departure from RBC, Mr. Gibbins has lent his expertise to help grow and focus various private and public companies globally.
Up-Listing and Cross-Listing Options
Mr. Gibbins said, "It is an absolute pleasure to be working with a company that is focused on functional health and wellness, while providing consumers premium quality products. My primary focus will be to advise on PsyKey's financial strategies, including up-listing and cross-listing options and other foreign stock exchange opportunities, as well as identifying key personnel to provide a multi-disciplinary team to support all aspects of the business. I look forward to being a pillar of support in this new and exciting Company."
"Having access to a world-class mycologist and a team that believes in a multi-disciplined, functional approach to mental health is what excited me the most," commented Ms. Lawlor. "I am thrilled to be working with the PsyKey team to advise on all aspects relating to mental health and innovative ways to bring access to mental health care to people in need."